HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dirk Schürmann Selected Research

Therapeutics

11/2019Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
1/2016Lung perfusion and emphysema distribution affect the outcome of endobronchial valve therapy.
11/2012Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
12/2007Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon(®)) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
10/2007Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
10/2006Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
5/2006Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
12/2005Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dirk Schürmann Research Topics

Disease

8Infections
01/2022 - 12/2004
5HIV Infections (HIV Infection)
01/2017 - 10/2006
3Disease Progression
08/2020 - 05/2006
3Acquired Immunodeficiency Syndrome (AIDS)
11/2019 - 10/2007
3Hepatitis B
10/2006 - 08/2002
1Hypernatremia
06/2021
1Cholangitis
06/2021
1Cysts
06/2021
1Lung Diseases (Lung Disease)
04/2021
1Blister (Bulla)
02/2021
1Erythema Multiforme
02/2021
1COVID-19
08/2020
1Headache (Headaches)
01/2020
1Neoplasms (Cancer)
12/2019
1Pleural Effusion (Pleural Effusions)
12/2019
1Encephalitis (Encephalitis, Rasmussen)
11/2019
1Toxoplasmosis
11/2019
1Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
11/2019
1Immune Reconstitution Inflammatory Syndrome
11/2019
1Hepatitis C
01/2016
1Emphysema
01/2016
1Herpes Zoster
04/2015
1Inflammation (Inflammations)
03/2014
1Lymphopenia (Lymphocytopenia)
06/2013
1Mannose-Binding Protein Deficiency
06/2013
1Hodgkin Disease (Hodgkin's Disease)
11/2012
1Coinfection
01/2010
1Liver Diseases (Liver Disease)
01/2010
1Soft Tissue Infections
02/2009
1Syphilis
01/2009
1Virus Diseases (Viral Diseases)
10/2007
1Chronic Hepatitis B
10/2006
1Nausea
05/2006
1Drug Hypersensitivity (Drug Allergy)
05/2006
1Diarrhea
05/2006
1Pneumonia (Pneumonitis)
12/2005
1Lipodystrophy
11/2005
1Lipomatosis
11/2005

Drug/Important Bio-Agent (IBA)

4Pharmaceutical PreparationsIBA
01/2020 - 05/2006
3NucleosidesIBA
01/2022 - 11/2019
3AntigensIBA
01/2022 - 10/2006
3RNA (Ribonucleic Acid)IBA
01/2020 - 05/2006
3Ritonavir (Norvir)FDA Link
11/2019 - 05/2006
3Lamivudine (Epivir)FDA Link
10/2006 - 08/2002
3Tenofovir (Viread)FDA Link
10/2006 - 08/2002
2Antiviral Agents (Antivirals)IBA
01/2022 - 05/2006
2Reverse Transcriptase InhibitorsIBA
01/2022 - 11/2019
2PerforinIBA
02/2021 - 01/2017
2Protease Inhibitors (Protease Inhibitor)IBA
01/2010 - 05/2006
2Enfuvirtide (Fuzeon)FDA Link
12/2007 - 10/2007
2Proteins (Proteins, Gene)FDA Link
12/2007 - 10/2007
1ulonivirineIBA
01/2022
1HLA-DR Antigens (HLA-DR)IBA
01/2022
1Praziquantel (Biltricide)FDA Link
06/2021
1Albendazole (Albenza)FDA Link
06/2021
1GlucocorticoidsIBA
04/2021
1Heme (Haem)IBA
02/2021
1Biomarkers (Surrogate Marker)IBA
08/2020
1islatravirIBA
01/2020
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2020
1Peptide Hydrolases (Proteases)FDA Link
11/2019
1EnzymesIBA
01/2016
1VaccinesIBA
04/2015
1IntegrinsIBA
03/2014
1Phenobarbital (Luminal)FDA Link
03/2014
1AntibodiesIBA
06/2013
1Mannose-Binding Lectin (Mannan-Binding Lectin)IBA
06/2013
1ProdrugsIBA
10/2012
1fostemsavirIBA
10/2012
1BMS-626529IBA
10/2012
1vicrivirocIBA
01/2010
1VancomycinFDA LinkGeneric
02/2009
1Linezolid (Zyvox)FDA Link
02/2009
1Indicators and Reagents (Reagents)IBA
01/2009
1Hepatitis B virus P proteinIBA
10/2006
1Triglycerides (Triacylglycerol)IBA
05/2006
1Nelfinavir (Viracept)FDA Link
05/2006
1lamivudine drug combination abacavirFDA Link
05/2006
1fosamprenavir (Lexiva)FDA Link
05/2006
1Ceftriaxone (Ceftriaxon)FDA LinkGeneric
12/2005
1Erythromycin (Erycette)FDA LinkGeneric
12/2005
1Anti-Bacterial Agents (Antibiotics)IBA
12/2005
1Third Generation CephalosporinsIBA
12/2005
1Moxifloxacin (Avelox)FDA Link
12/2005
1FluoroquinolonesIBA
12/2005
1adefovir dipivoxil (Hepsera)FDA Link
12/2004
1adefovirIBA
12/2004

Therapy/Procedure

8Therapeutics
11/2019 - 12/2005
3Highly Active Antiretroviral Therapy (HAART)
04/2014 - 11/2005
2Catheters
06/2021 - 12/2019
2Art Therapy
11/2019 - 04/2015
1Punctures
06/2021
1Pleurodesis
12/2019
1Transplantation
06/2013